End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
78,400 KRW | -4.16% | +4.53% | +13.95% |
May. 16 | Yuhan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
Strengths
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- With an expected P/E ratio at 41.94 and 30.58 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.95% | 4.27B | B- | ||
+19.29% | 80.29B | A | ||
+15.44% | 9.2B | A- | ||
-18.33% | 4.67B | A- | ||
+43.39% | 4.49B | - | ||
+10.89% | 2.25B | B | ||
-28.40% | 2.13B | C- | ||
+15.93% | 2.1B | - | - | |
-43.17% | 1.78B | - | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A000100 Stock
- Ratings Yuhan Corporation